1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Benchmark Holdings plc

Benchmark Holdings plc

BHCCF
Benchmark Holdings plcUS flagOther OTC
0.37
USD
- -
- -
225.11MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
0.14
0.2
0.28
0.22
0.26
0.27
0.25
0.22
0.17
0.19
0.23
0.14
0.12
0.07
Basic EPS, GAAP
0.02
0.03
-0.01
-0.06
-0.04
-0.01
-0.01
-0.15
-0.05
-0.02
-0.05
-0.03
-0.05
0.06
Free Cash Flow per Basic Share
0.01
0.03
-0.04
-0.12
-0.07
-0.04
-0.07
-0.04
-0.02
-0.02
- -
0.02
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.05
0.08
0.08
- -
-0.04
-0.05
-0.05
-0.2
-0.23
-0.23
-0.26
0.25
0.2
0.29
Tangible Book Value per Share
0.03
0.06
0.23
0.13
0.04
0.06
0.11
0.06
0.08
0.08
0.11
0.1
0.15
0.26
Basic Weighted Avg Shares
137
137
127
202
418
523
532
559
625
669
698
732
740
740
Sales/Revenue/Turnover
19
28
35
44
109
140
132
124
106
125
158
104
90
51
Operating Margin (%)
19.62
20.04
7.15
-19.63
-6.88
-9.5
-1.69
-36.64
-8.44
-3.43
-3.58
-13.01
-32.59
-62.05
Depreciation Expense
- -
1
1
4
17
23
25
83
29
25
39
37
34
26
Net Income, GAAP
3
4
-1
-12
-18
-7
-5
-84
-33
-13
-32
-23
-39
46
Effective Tax Rate (%)
21.25
11.54
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
15
15.59
-3.72
-27.12
-16.77
-5.31
-3.8
-67.62
-31.19
-10.31
-20.35
-22.26
-43.67
90.6
Working Capital
5
7
23
13
69
34
49
71
90
61
75
75
107
189
LT Debt
3
2
- -
- -
37
36
79
100
104
110
93
82
3
2
Total Equity
8
12
37
92
368
359
382
310
295
280
323
283
224
303
Return on Invested Capital (%)
- -
31.59
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
34.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
48.92
-12.62
- -
- -
- -
- -
- -
- -
- -
- -
- -
-23.84
23.74

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'25
Mar'25
ST Debt
69
73
79
LT Borrowings
- -
- -
- -
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
740
740
742
Market Capitalization
- -
280
210

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'25
Mar'25
Total Current Assets
253
244
295
Cash, Cash Equivalents & STI
23
14
208
Accounts Receivable, Net
18
41
63
Inventories
24
24
24
Total Current Liabilities
146
142
106
Payables & Accruals
- -
- -
- -
ST Debt
69
73
79
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.4%
-5.56%
-20.65%
Free Cash Flow
-680.53%
-1,439.32%
-112.8%
Net Income, GAAP
241.66%
13.99%
70.5%
Sales/Revenue/Turnover
17.13%
-3.49%
-13.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
54
44
34
36
104
2024
25
27
31
-21
90
2025
18
23
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
-0.01
- -
-0.03
2024
-0.01
- -
-0.01
-0.03
-0.05
2025
-0.01
0.12
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Patrick Waty
Full Time Employees
800
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
4 Park Square Sheffield United Kingdom S35 2PH
IPO Date
Jun 19, 2018
Website
benchmarkplc.com
Similar Companies
Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)
Dali Pharmaceuticalco.,Ltd (603963.SS)
Shield Therapeutics plc (SHIEF)
Societal CDMO, Inc. (SCTL)
J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS)
Leef Brands Inc. (LEEEF)
Business
Benchmark Holdings plc is an aquaculture biotechnology company that provides specialized products and solutions in advanced nutrition and health to support sustainable food production for aquaculture producers worldwide. The company operates through two primary segments: Advanced Nutrition, encompassing INVE Aquaculture, which manufactures and supplies live feeds such as artemia, early-stage specialist diets, nutritional additives, probiotics, and environmental solutions for shrimp and marine fish hatcheries; and Health, which offers sea lice treatments including Ectosan Vet, CleanTreat medicinal bath purification systems, and Salmosan Vet for salmon farming. Benchmark serves key markets in shrimp and finfish aquaculture, with operations spanning Europe including the United Kingdom, Norway, Iceland, and the Faroe Islands; Asia including Vietnam, China, and India; the Americas including Chile, Ecuador, and Canada; and other international regions. Founded in 2000 and headquartered in Sheffield, United Kingdom, the company recently completed the sale of its Genetics business to Novo Holdings in March 2025 for up to £260 million, enabling a strategic refocus on Advanced Nutrition and Health alongside a return of capital to shareholders via tender offer and subsequent delisting from AIM London and Euronext Growth Oslo in August 2025; it also pursued expansion through the acquisition of INVE Aquaculture Holding B.V. in 2025 to bolster its early-life stage nutrition portfolio.

Company News

APIChat

  • defenseworld.net

    Benchmark (OTCMKTS:BHCCF) Shares Down 7.7% – Here’s Why